ALEXANDRIA, Va., April 15 -- United States Patent no. 12,600,786, issued on April 14, was assigned to R.G.C.C. Holdings AG (Zug, Switzerland).
"C-met and TMX2 antibodies" was invented by Ioannis Papasotiriou (Oberageri, Switzerland).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides: a novel method for the production of truly fully human monoclonal antibodies against specific antigens of our choice using isolated human blood cells. These antigens may include but are not limited to peptide sequences found in c-met and TMX2 proteins; an antibody specific for c-met protein produced with said method; an antibody specific for TMX2 protein produced with said method; and a new means and me...